Kiniksa Pharmaceuticals International
- Country
- 🇧🇲Bermuda
- Ownership
- -
- Employees
- 297
- Market Cap
- $1.9B
- Introduction
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Target Recruit Count
- 145
- Registration Number
- NCT05198310
- Locations
- 🇺🇸
Carewell Arthritis Center, Apple Valley, California, United States
🇺🇸Medvin Clinical Research, Whittier, California, United States
🇺🇸Inland Rheumatology Clinical Trials, Upland, California, United States
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT04497662
- Locations
- 🇺🇸
PPD Clinic, Austin, Texas, United States
🇦🇺Q-Pharm Pty Ltd, Herston, Queensland, Australia
KPL-301 for Subjects With Giant Cell Arteritis
- Conditions
- Giant Cell Arteritis
- Interventions
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT03827018
- Locations
- 🇺🇸
Site 1703, Sarasota, Florida, United States
🇺🇸Site 1708, Tampa, Florida, United States
🇺🇸Site 1706, Atlanta, Georgia, United States
News
Kiniksa Pharmaceuticals Advances KPL-387 Phase 2/3 Trial for Recurrent Pericarditis
Kiniksa Pharmaceuticals announced the trial design for its Phase 2/3 clinical study of KPL-387, a monoclonal antibody targeting IL-1R1, in recurrent pericarditis patients.
Kiniksa Reports Strong ARCALYST Growth, Advances KPL-387 for Recurrent Pericarditis Development
ARCALYST achieved remarkable growth with $417 million in 2024 net product revenue, representing a 79% year-over-year increase, with projected 2025 revenue between $560-580 million.
Urticaria Clinical Trial Pipeline Heats Up with Novel Therapies in Development
The urticaria treatment landscape is evolving, with over 20 companies developing more than 25 novel therapies to address unmet patient needs.